NCI-H1299-EGFP

The NCI-H1299 GFP cells, modified to include a reporter in the DAPK1 gene, are not only useful for studying specific gene activation but also provide a broader understanding of how cells react to epigenetic drugs globally. By using a technique called Cap Analysis of Gene Expression (CAGE), researchers have been able to detail changes in where transcription starts across the genome in response to treatments with DNMTi (DAC), HDACi (SAHA or SB939), or their combinations. This method reveals not just the expected reactivation of the DAPK1 gene but also the emergence of new transcription start sites, called treatment-induced non-annotated TSSs (TINATs), especially under drug treatment. These new start sites are typically located in regions of the genome that do not usually produce proteins and lead to the creation of new RNA molecules that could potentially code for proteins.

Further analysis shows that these new RNA molecules can sometimes merge with existing ones to form what are known as TINAT-exon fusion transcripts. Depending on how these transcripts are spliced, they can translate into new, atypical proteins. This process has been confirmed through laboratory techniques that demonstrate these transcripts can indeed lead to the production of new protein forms. These proteins might interact abnormally within the cell or be recognized as foreign by the immune system, potentially offering new targets for cancer therapy.

The activation of these TINATs involves intricate changes in both DNA methylation and histone modifications, illustrating a complex interaction between these epigenetic factors under drug treatment. Particularly, the combined use of DAC and SB939 shows a greater effect, boosting the expression of these novel transcripts more than when either drug is used alone. Understanding these interactions and their outcomes helps clarify how epigenetic therapies alter cell behavior and opens up possibilities for new cancer treatments that leverage these complex molecular changes.